Rockville, Maryland, June 12, 2002
Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that they have initiated NicVAX (Nicotine Conjugate Vaccine) phase I testing in humans. NicVAX is a proprietary and novel investigational vaccine designed to help the body develop antibodies that bind to nicotine and block it from reaching the brain.
If shown to be safe and effective in subsequent clinical trials, NicVAX may help millions of people worldwide kick their addiction to cigarettes and tobacco products. “NicVAX is an entirely new approach to fighting and preventing nicotine addiction,” said David J. Gury, Nabi Biopharmaceuticals chairman, president and chief executive officer
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!